FibroBiologics (NASDAQ:FBLG) Upgraded at Wall Street Zen
by Renee Jackson · The Cerbat GemWall Street Zen upgraded shares of FibroBiologics (NASDAQ:FBLG – Free Report) to a sell rating in a research note published on Saturday morning.
Several other equities research analysts also recently issued reports on FBLG. Weiss Ratings reiterated a “sell (e+)” rating on shares of FibroBiologics in a report on Thursday, January 22nd. D. Boral Capital reiterated a “hold” rating on shares of FibroBiologics in a report on Thursday, March 26th. Finally, HC Wainwright decreased their price target on FibroBiologics to $80.00 and set a “buy” rating for the company in a report on Thursday, February 26th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $110.00.
Get Our Latest Stock Report on FibroBiologics
FibroBiologics Trading Down 0.7%
Shares of FibroBiologics stock opened at $1.37 on Friday. The stock has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $6.58. FibroBiologics has a 12-month low of $1.03 and a 12-month high of $30.60. The company has a market capitalization of $4.81 million, a P/E ratio of -0.16 and a beta of 1.07.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.06. On average, analysts predict that FibroBiologics will post -0.53 EPS for the current year.
Insider Transactions at FibroBiologics
In other FibroBiologics news, CFO Jason Davis acquired 3,500 shares of FibroBiologics stock in a transaction on Monday, March 2nd. The stock was purchased at an average price of $8.20 per share, for a total transaction of $28,700.00. Following the purchase, the chief financial officer directly owned 3,500 shares of the company’s stock, valued at $28,700. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last ninety days, insiders acquired 9,574 shares of company stock valued at $72,886. 13.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in FBLG. AQR Capital Management LLC purchased a new position in shares of FibroBiologics during the 1st quarter valued at $29,000. XTX Topco Ltd lifted its position in shares of FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after buying an additional 28,276 shares during the last quarter. AMG National Trust Bank purchased a new position in shares of FibroBiologics during the 4th quarter valued at $31,000. Jane Street Group LLC purchased a new position in shares of FibroBiologics during the 4th quarter valued at $34,000. Finally, Marshall Wace LLP purchased a new position in shares of FibroBiologics during the 2nd quarter valued at $49,000.
About FibroBiologics
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.